Markets:

Overview

News

Currencies

International

Treasuries

Medtronic (NY:MDT)

77.57 -1.01 (-1.29%)

Streaming Delayed Price Updated: 12:27 PM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Medtronic

< Previous 1 2 3 4 5 6 7 8 9

...

64 65 Next >

J&J Shatters Estimates as Oncology and MedTech Power 2026 Outlook Higher

April 15, 2026

Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared...

Via MarketMinute

Topics Economy Intellectual Property

Inflation Fever Breaks: March PPI Data Offers Unexpected Relief to Markets

April 15, 2026

The financial markets received a much-needed breath of fresh air this week as the Bureau of Labor Statistics released the Producer Price Index (PPI) report for March 2026. Final demand prices rose by...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Boston Scientific’s $14.9 Billion Bet: The Strategic "Homecoming" to Neurovascular Dominance

April 15, 2026

As of April 15, 2026, the medical technology landscape is bracing for its most significant transformation in years. Boston Scientific (NYSE:BSX) is moving steadily toward the finalization of its $14.9...

Via MarketMinute

Topics Economy

Medtronic PLC (NYSE:MDT): A Durable Dividend Stock for Income Investors ↗

April 09, 2026

Via Chartmill

Consolidation Fever: Boston Scientific’s $14.9 Billion Bet on Penumbra Signals New Era in MedTech M&A

April 15, 2026

In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN) for approximately...

Via MarketMinute

Topics Economy

MedTech Surge and Oncology Resilience Drive Johnson & Johnson to Q1 Earnings Beat

April 14, 2026

In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of...

Via MarketMinute

Topics Bankruptcy Earnings Economy

Johnson & Johnson Shatters Expectations in Q1 2026, Raising Full-Year Outlook as Healthcare Giant Pushes Toward $100 Billion Milestone

April 14, 2026

NEW BRUNSWICK, N.J. — In a powerful display of resilience and strategic execution, Johnson & Johnson (NYSE: JNJ) reported first-quarter 2026 financial results that exceeded Wall Street estimates across...

Via MarketMinute

Topics Economy Intellectual Property

The New J&J: A 2026 Deep Dive into the Global Healthcare Titan

April 14, 2026

As of April 14, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different entity than it was only three years ago. Following the successful spin-off of its consumer health division, Kenvue,...

Via Finterra

Topics Artificial Intelligence Death Economy

The Teleflex Pivot: Inside the $1 Billion Share Buyback and Strategic Breakup

April 09, 2026

Disclaimer: This content is intended for informational purposes only and is not financial advice. Today’s date is April 9, 2026. Introduction In the high-stakes arena of medical technology, few stories...

Via Finterra

Topics Economy World Trade

Telix Strengthens Board with Additional Director Appointments

April 08, 2026

From Telix Pharmaceuticals Limited

Via GlobeNewswire

3 Dividend Stocks to Double Up On Right Now ↗

April 08, 2026

From energy to healthcare, this trio of reliable dividend payers are worth a deep dive today.

Via The Motley Fool

Topics Economy

This Healthcare Stock Has No Debt and a Near-Monopoly in Its Market ↗

April 07, 2026

The company is a picture of financial stability.

Via The Motley Fool

Hologic, Inc. (NASDAQ: HOLX): A New Chapter as a Women’s Health Powerhouse

April 07, 2026

Today marks a definitive turning point for Hologic, Inc. (NASDAQ: HOLX). As the company prepares to finalize its $18.3 billion acquisition by private equity giants Blackstone and TPG, it stands as a...

Via Finterra

Topics Artificial Intelligence Retirement World Trade

Robotic Revolution in the Electrophysiology Lab: FDA Clears Stereotaxis Synchrony System

April 06, 2026

ST. LOUIS – April 6, 2026 – In a milestone that signals a paradigm shift for cardiac care, Stereotaxis (NYSE American: STXS) has received FDA 510(k) clearance for its Synchrony™ System. The approval...

Via MarketMinute

Topics Artificial Intelligence

Stereotaxis Secures FDA Clearance for Synchrony™ System, Completing Its Vision for the Robotic "Digital Cockpit"

April 06, 2026

ST. LOUIS — April 6, 2026 — Stereotaxis (NYSE: STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias and other endovascular procedures, announced today that...

Via MarketMinute

The “New BD”: A Deep-Dive Research Report on Becton, Dickinson and Company (BDX) in 2026

April 03, 2026

As of April 3, 2026, the medical technology landscape is undergoing a radical transformation, and few companies embody this evolution more than Becton, Dickinson and Company (NYSE: BDX). Known...

Via Finterra

Topics Artificial Intelligence

The Martha Transformation: A Deep Dive into Medtronic’s 2026 Pivot

April 03, 2026

As of April 3, 2026, Medtronic plc (NYSE: MDT) stands at a critical inflection point in its 77-year history. Once viewed as a lumbering healthcare conglomerate burdened by its own scale, the...

Via Finterra

Topics Artificial Intelligence Initial Public Offering Product Recall

Med-Tech Resilience: AngioDynamics Pivot Pays Off with Double-Digit Growth and Profitability

April 02, 2026

The medical technology sector has long been a bellwether for the health of the broader economy and the efficiency of the healthcare system. Today, April 2, 2026, AngioDynamics (NASDAQ:ANGO) provided...

Via MarketMinute

Topics Economy Retirement

The Medtronic Transformation: A Deep Dive into the Future of a MedTech Titan

April 01, 2026

As of April 1, 2026, the global medical technology landscape is undergoing a profound shift, and at the center of this evolution is Medtronic plc (NYSE: MDT). Long regarded as the "sleeping giant" of...

Via Finterra

Topics Artificial Intelligence Economy Initial Public Offering

The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future

April 01, 2026

As we enter the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) stands as a starkly different entity than the consumer-facing conglomerate that defined the 20th century. Having successfully shed...

Via Finterra

Topics Artificial Intelligence Earnings Economy

This Dividend King Is Down 26%. When Will It Bounce Back?

March 31, 2026

Abbott Laboratories is down 26% from its 52-week high due to a soft quarter. With 54 consecutive years of dividend hikes and guidance calling for mid-single-digit organic sales growth plus 10% EPS...

Via Barchart.com

Topics Artificial Intelligence

Deep Dive: Boston Scientific (BSX) and the New Era of Medical Device Dominance

March 31, 2026

Date: March 31, 2026 Introduction Boston Scientific Corporation (NYSE: BSX) finds itself at a critical crossroads this morning. After a year of record-breaking growth and the successful launch of its...

Via Finterra

Topics Lawsuit Product Recall

Stock Market Today, March 30: Boston Scientific Falls After Delivering Underwhelming Trial Results ↗

March 30, 2026

Today, March 30, 2026, investors send Boston Scientific shares lower as they dig deeper into the company's latest trial update.

Via The Motley Fool

Topics Stocks

Is Intuitive Surgical a Buy Right Now? ↗

March 27, 2026

The healthcare leader has seen better times.

Via The Motley Fool

Topics World Trade

5 Spin-Off Stocks That Could Reward Patient Investors in 2026 ↗

March 26, 2026

Via MarketBeat

Is Insulet Stock Underperforming the Dow?

March 21, 2026

Insulet has underperformed the Dow recently, yet analysts remain highly optimistic about the stock’s prospects.

Via Barchart.com

Topics Stocks

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗

March 20, 2026

This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗

March 20, 2026

This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.

Via The Motley Fool

2 Stocks That Could Create Lasting Generational Wealth ↗

March 17, 2026

These investments could help you sleep peacefully at night.

Via The Motley Fool

Topics World Trade

Worried the AI Hype Won't Last? These Dividend Stocks Offer Safer Exposure ↗

March 17, 2026

You don't have to go all in to profit from AI.

Via The Motley Fool

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

64 65 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.